AiM Medical Robotics recently announced that it has raised US$3.4 million in seed funding, led by IQ Capital and Surrey Capital Partners. Other investors include The Lambda Fund, Triple Ring Technologies, and Worcester Polytechnic Institute, among additional inside investors.
As of the close of this funding, Samantha Surrey, founder of Surrey Capital Partners, has joined AiM’s board of directors too.
AiM will use the capital to accelerate development of its “industry-first” magnetic resonance imaging (MRI)-compatible robotics platform, which the company says is designed to improve outcomes for patients undergoing neurosurgery for cancer or functional brain disorders, such as Parkinson’s disease and epilepsy, and provide cost savings to hospitals by eliminating errors and reducing procedure times.
The company will also continue to grow its team across research, engineering, and clinical and medical affairs.
“AiM is on an exciting journey to develop and commercialise an industry-first in robot-assisted surgery with our MRI-compatible robotics platform” said Bob Cathcart, CEO of AiM. “I am honoured to have the support of our investors as we continue building our team of experts in robotics and medicine, and as we work towards our north star of improving patient outcomes in neurosurgery.”
AiM has also announced the appointment of Jonathan Sackier as its chief medical officer and the appointment of Gregory Cole as its chief technology officer in recent weeks.
